|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study supports the view that variants in the rs6684439 SNP of IL-6R is associated with a lower risk of HBV-related HCC, and this could provide valuable clues to understanding the mechanisms underlying susceptibility to this malignant disease.
|
24668548 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The study revealed that the IL-6(-572) GC genotype shared a positive association with hepatitis among controls, and a negative association with cirrhosis and consequent HCC development among carriers.
|
24841049 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggested that rs1800796 polymorphism of IL-6 gene was associated with susceptibility to HBV-related HCC in a male Chinese Han population.
|
24530755 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, IL-6-174 G/C, but not -572 G/C polymorphism could be a candidate for susceptibility to HCC.
|
24318992 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma.
|
23674845 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For T helper (Th) 1 genes (IFNgamma, IL-6 and IL-12), relative to the putative high-activity genotypes, individual low-activity genotypes were associated with statistically non-significant increases in HCC risk.
|
19126646 |
2009 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, IL-6 rs1474358 GG genotype had a favourable factor for HCC establishment.
|
28340949 |
2017 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant associations were detected between IL6-572 C>G and chronic hepatitis B outcome in this study; i.e., LC occurrence on CH (OR = 0.16-1.27, P = 0.13- 0.71) and HCC occurrence on LC (OR = 1.04-1.23, P = 0.89-0.60) of heterozygotes and homozygotes for G allele in referent comparison to homozygotes for common allele (C/C genotype), and time interval to HCC (RH = 0.67-1.00; P = 0.14-0.99).
|
12754410 |
2003 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6-174 Promoter Polymorphism and Susceptibility to Hepatitis B Virus Infection as a Risk Factor for Hepatocellular Carcinoma in Iran.
|
27268603 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic genotypes predisposing the APOBEC3B-UNG imbalance in IL6-presenting microenvironment promote HCC development, possibly via promoting the generation of high-risk HBV mutations.
|
31152021 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-seven IL-6 variants were tested for biological activity on a human hepatoma and a mouse hybridoma cell line.
|
1321818 |
1992 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutagenesis of a region of human interleukin (IL)-6 which is important for triggering signal transduction via the IL-6 receptor beta-chain (gp130) has lead to the isolation of a variant of human IL-6 (IL-6.Q160E/T163P), which could antagonize the biological activity of wild type IL-6 on the human EBV transformed B cell line CESS and the human hepatoma cell line HepG2.
|
7578977 |
1995 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, both IL-1β and IL-6 were inversely associated with plasma MBL2 level.The mutations in MBL2 could lead to compromised innate immunity, and possibly lead to elevated HCC risk, and a novel haplotype HXB has been identified with a rate of 12.5%.
|
27557564 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that donor IL6 rs2069852 polymorphisms may be a potential genetic marker for HCC recurrence after liver transplantation in the Han Chinese population.
|
27368337 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The protective effect of female gender against the occurrence of HCC occurs mainly among carriers of IL-6 high producer phenotypes.
|
19940521 |
2009 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNFα (G-238A, C-863A, G-308A), IL6 (C-174G), and IL1β (C-31T, C-511T) SNPs were assessed in 232 alcoholics and 253 HCV-infected patients with biopsy-proven cirrhosis, prospectively followed-up and screened for HCC.
|
24751829 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that transient inhibition of HNF4α initiates transformation of immortalized hepatocytes through a feedback loop consisting of miR-24, IL6 receptor (IL6R), STAT3, miR-124 and miR-629, suggesting a central role of HNF4α in HCC.
|
27477312 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have previously shown that the responsiveness to IL-6 is different in hepatoma and human primary hepatocytes.
|
7545121 |
1995 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We measured the cytokine levels of Th1 (IL-2 and IL-2R), Th2 (IL-10) and the pro-inflammatory cytokines (IL-6 and IL-6R and TNF and TNF-RI and II) by the ELISA technique in the sera of 33 hepatocellular carcinoma (HCC) patients and 20 chronic liver disease (CLD) patients.
|
16425355 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 production by human hepatoma lines is related to a low degree of cell differentiation.
|
8210716 |
1993 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma.
|
27213590 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
And HSCs could secrete soluble factors, such as interleukin-6 (IL-6), vascular endothelial cell growth factor (VEGF), and stromal-derived factor-1 (SDF-1) to facilitate HCC progression.
|
30800209 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the expression of LOXL2 protein, in addition to carbonic anhydrase IX (CAIX), keratin 19, epithelial cell adhesion molecule, and interleukin 6, in 105 resected hepatocellular carcinomas (HCCs) by immunohistochemistry.
|
29938458 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report here that interleukin-6 (IL-6), the principal cytokine mediating the synthesis of most acute-phase proteins in the liver, downregulates the production of factor XII by the human hepatoma cell line HepG2 by up to 75%.
|
9269767 |
1997 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Levels of coenzyme Q10, vitamin E, oxidative stress (malondialdehyde), antioxidant enzymes activity (superoxidase dismutase, catalase, and glutathione peroxidase), and inflammatory markers (high sensitivity C-reactive protein; tumor necrosis factor-α; and interleukin-6) were measured; (3) Results: Patients with HCC had a significantly lower levels of coenzyme Q10 (<i>p</i> = 0.01) and oxidative stress (<i>p</i> < 0.01), and significantly higher levels of antioxidant enzymes activities and inflammation after surgery (<i>p</i> < 0.05).
|
28054958 |
2017 |